This is consistent with CXCR3’s established role in guiding T cell trafficking (50, 53, 55) and with CXCR3+ T cells being recruited to CXCL10-rich tumor sites to augment antitumor immunity (74–77). The gene discussed is CXCL10; the disease is neoplasm.